Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model

Robert A. Kazmierczak; Bakul Dhagat-Mehta; Elke Gulden; Li Lee; Lixin Ma; Clintin P. Davis-Stober; Austen A. Barnett; Chiswili Yves Chabu

doi:10.18632/oncotarget.27769

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model

Robert A. Kazmierczak _, Bakul Dhagat-Mehta, Elke Gulden, Li Lee, Lixin Ma, Clintin P. Davis-Stober, Austen A. Barnett and Chiswili Yves Chabu

Oncotarget. 2020; 11:3943-3958. https://doi.org/10.18632/oncotarget.27769

Metrics: PDF 654 views | Full Text 2609 views | ?

Abstract

Robert A. Kazmierczak1^,*, Bakul Dhagat-Mehta1^,*, Elke Gulden2, Li Lee3^,4, Lixin Ma3^,4, Clintin P. Davis-Stober5, Austen A. Barnett6 and Chiswili Yves Chabu7

1 Cancer Research Center, Columbia, MO, USA

2 Department of Immunobiology, Yale University, New Haven, CT, USA

3 Department of Radiology and Department of Physics and Astronomy, University of Missouri, Columbia, MO, USA

4 Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO, USA

5 Department of Psychological Sciences, Institute for Data Science & Informatics, University of Missouri, Columbia, MO, USA

6 Department of Biology, DeSales University, Center Valley, PA, USA

7 Division of Biological Sciences, University of Missouri, Columbia, MO, USA

* These authors contributed equally to this work

Correspondence to:

Chiswili Yves Chabu,

email:

[email protected]

Keywords: salmonella; cancer targeting; prostate cancer; immunotherapy; TRAMP

Received: July 02, 2020 Accepted: September 24, 2020 Published: November 03, 2020

Copyright: © 2020 Kazmierczak et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Conventional cancer chemotherapies are not fully efficacious and do not target tumors, leading to significant treatment-related morbidities. A number of genetically attenuated cancer-targeting bacteria are being developed to safely target tumors in vivo. Here we report the toxicological, tumor-targeting, and efficacy profiles of Salmonella enterica serovar Typhimurium CRC2631 in a syngeneic and autochthonous TRAMP model of aggressive prostate cancer. CRC2631 preferentially colonize primary and metastatic tumors in the TRAMP animals. In addition, longitudinal whole genome sequencing studies of CRC2631 recovered from prostate tumor tissues demonstrate that CRC2631 is genetically stable. Moreover, tumor-targeted CRC2631 generates an anti-tumor immune response. Combination of CRC2631 with checkpoint blockade reduces metastasis burden. Collectively, these findings demonstrate a potential for CRC2631 in cancer immunotherapy strategies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27769

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model

Abstract